CC2D1A抗体;CC2D1A Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13028(CC2D1A Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P13028(CC2D1A Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The CC2D1A antibody targets the CC2D1A (Coiled-Coil and C2 Domain-Containing Protein 1A) protein, a ubiquitously expressed factor involved in multiple cellular processes. CC2D1A contains four DM14 domains and a C2 domain, enabling interactions with proteins like Freud-1 and components of the NF-κB signaling pathway. It regulates transcription, cell division, and neurotransmitter signaling, with roles in neuronal development and synaptic plasticity. Mutations in the CC2D1A gene are linked to autosomal recessive intellectual disability and neurodevelopmental disorders, including nonsyndromic mental retardation 3 (MRT3). Overexpression studies in HEK293 cells suggest its involvement in serotonin receptor 1A (5-HT1A) repression.

CC2D1A antibodies, often monoclonal or polyclonal, are critical tools for detecting the protein via Western blotting, immunofluorescence, or immunoprecipitation. They help elucidate CC2D1A’s subcellular localization (nucleus, cytoplasm, or centrosomes) and interactions in disease models. Research using these antibodies has highlighted CC2D1A’s dual roles as a transcription factor and signaling scaffold, particularly in brain development and cancer pathways. Commercial antibodies are typically validated for specificity using knockout controls. Ongoing studies focus on its potential as a biomarker or therapeutic target in neuropsychiatric conditions.